Takeda To Add Mid-Stage Autoimmune Disease Candidate For $4B

Takeda Pharmaceutical Co Ltd TAK will acquire NDI-034858 from Nimbus Therapeutics, an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor for multiple autoimmune diseases.
It is in an ongoing Phase 2b study in active psoriatic arthritis, and Takeda plans to investigate it for inflammatory bowel disease (IBD) and other autoimmune diseases.
Nimbus recently disclosed topline results from a Phase 2b study evaluating NDI-034858 in patients with moderate-to-severe plaque psoriasis.
Takeda intends to present results from this Phase 2b study early in 2023. NDI-034858 is anticipated to enter Phase 3 in psoriasis in 2023.
"This program further expands Takeda's GI clinical programs and therapeutic focus," said Andy Plump, president of R&D at Takeda.
Under the terms of the agreement, Takeda will pay Nimbus $4 billion upfront and two milestone payments of $1 billion each upon achieving annual net sales of $4 billion and $5 billion.
The upfront payment will be primarily funded by cash on hand. The transaction is expected to be finalized before the end of FY2022.
Takeda ended the 30 September quarter with cash of $5.5 billion.
Price Action: TAK shares are up 2.75% at $15.33 on the last check Tuesday.